Sign in
Taking peoplePhase 3

Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency

Key facts

Who runs it
Angelica Lindén Hirschberg
Where
Sweden2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
40 people, planned
Started
12 Feb 2026
Expected to end
31 Dec 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rituximab (Arm A)
  • Rituximab (Arm B)
Record updated
3 April 2026

Who can take part

Age
18 years to 38 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • The subject has given their written consent to participate in the trial
  • Autoimmune POI (FSH > 25 IU/L) including the presence of oligo/amenorrhea lasting at least 4 months, and elevated FSH levels (FSH > 25 IU/L) confirmed on two separate occasions, with measurements taken at least 4 weeks apart and Addison's disease or ab positivity for 21-hydroxylase or other relevant autoantibodies (SCC, 17-OH, NALP5)
  • 18-38 years of age
  • Body mass index between 19-30
  • Willing to use effective non-hormonal contraceptive (such as intra uterine device (IUD), sexual abstinence, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) method during the 18-month study period

Who cannot take part

  • Hormone replacement therapy within four weeks prior study entry
  • Concurrent treatment with other immunosuppressive drugs
  • Any vaccination within 4 weeks of infusion of study medication
  • Any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with rituximab or controlled ovarian hyperstimulation
  • Hypersensitivity to rituximab, any of the AxMPs, or any of the excipients (as detailed in the SmPC for the various IMPs)
  • Active, severe infection or JCV positivity
  • Active hepatitis B infection
  • Severe cardiac disease
  • Cancer
  • Vaginal bleeding of unknown etiology
  • Severe psychiatric disorder
  • Active thrombolic disorder (contraindicated for Ovirelle)
  • Moderate or severe impairment of kidney or liver function (contraindicated for Orgalutran); -
  • Severe immunosuppression
  • Benign tumours of the hypothalamus, pituitary, or ovarian pathology
  • Pregnant or lactating women

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 38 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Several autoimmune diseases such as Addison's disease are associated with failing ovarian function, known as premature ovarian insufficiency (POI), which can lead to early menopause and reduced fertility.The underlying cause of POI in these women is considered to be an immunological attack on the ovaries that causes them to not respond to hormonal stimulation from the brain. Hormone replacement effectively counteracts menopausal symptoms, but today there is no treatment to normalize or even improve fertility. As a patient with POI and an autoimmune diagnosis and the desire to become pregnant, you are asked to participate in the study. The aim of this study is to investigate whether immunomodulatory therapy can improve and ideally normalize ovarian function in women of childbearing age with autoimmune disease and proven POI. Patients with a male partner and a desire for children and who respond positively to the first ovarian stimulation will be offered in vitro fertilization (IVF) and will thus be allowed to complete the study. Other participating patients will undergo a total of three ovarian stimulations and treatment with first two infusions of the registered drug rituximab or placebo (inactive agent) and later two additional infusions where all patients receive rituximab. The first two infusions with rituximab or placebo are double-blind, which means that neither you nor the study staff know what you have received. Follow-up takes place up to 12 months after the last infusion.

The 2 groups in the trial

  • Group A 2 infusions with placebo or Rituximab, and then 2 infusions of RituximabExisting treatment, for comparison

    Randomized to 2 infusions of placebo or Rituximab (2g) with a 2-week interval between infusions 1 and 2 , and then 2 infusions of Rituximax (2g) ,after a 6-month interval between the first two and the last two infusions.

    Treatment: Rituximab (Arm A)

  • Group B , 2 infusions (2 g) RituximabExisting treatment, for comparison

    Group B a total of 2 infusions (2 g) with Rituximab, 2 weeks apart per occasion.

    Treatment: Rituximab (Arm B)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency - Double-blind, Placebo-contrelled, Randomized Study.
Criteria questions
Built from NCT07509840, who can take part
Record updated
3 April 2026